Literature DB >> 23435403

Infliximab-associated psoriasis in children with Crohn's disease may require withdrawal of anti-tumor necrosis factor therapy.

Tangra Broge, Nam Nguyen, Alan Sacks, Michael Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435403     DOI: 10.1097/MIB.0b013e3182802c93

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  5 in total

Review 1.  Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis-A Review.

Authors:  Abigail Cline; Andrew Berg; Gregory J Bartos; Lindsay C Strowd; Steven R Feldman
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

2.  Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.

Authors:  Estelle Fréling; Cédric Baumann; Jean-François Cuny; Marc-André Bigard; Jean-Luc Schmutz; Annick Barbaud; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2015-07-21       Impact factor: 10.864

Review 3.  Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis.

Authors:  Abigail Cline; Gregory J Bartos; Lindsay C Strowd; Steven R Feldman
Journal:  Children (Basel)       Date:  2019-09-11

Review 4.  Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives.

Authors:  Federico Diotallevi; Oriana Simonetti; Giulio Rizzetto; Elisa Molinelli; Giulia Radi; Annamaria Offidani
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

5.  Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients.

Authors:  P Andrade; S Lopes; R Gaspar; A Nunes; S Magina; G Macedo
Journal:  Dig Dis Sci       Date:  2018-01-18       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.